Abstract
Summary
Single doses of ergotamine tartrate (0.5 mg.), injected subcutaneously, produce definite vasoconstriction as indicated by a decrease in peripheral blood-flow. Less commonly, vasodilatation is produced, with increased blood-flow. No significant difference in blood-flow change after ergotamine was noted between normals and subjects with liver disease.
Get full access to this article
View all access options for this article.